Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 569-575

  Ardizzoni, Andrea ^a   Favaretto, Adolfo ^b   Boni, Luca ^b   Baldini, Editta ^b   Castiglioni, Federico ^b   Antonelli, Paola ^b   Pari, Franca ^b   Tibaldi, Carmelo ^b   Altieri, Alfonso M ^b   Barbera, Sante ^b   Cacciani, Giancarlo ^b   Raimondi, Mario ^b   Tixi, Lucia ^b   Stefani, Micaela ^b   Monfardini, Silvio ^b   Antilli, Antonio ^b   Rosso, Riccardo ^b   Paccagnella, Adriano ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CISPLATIN; CLAVULANIC ACID; DEXAMETHASONE; ETOPOSIDE; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; AGE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; PATHOLOGY; SMALL CELL CARCINOMA;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 20044392099     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.11.140     Document Type: Article

References (20)

1. Ardizzoni A, Grossi F: Update on the treatment of small cell lung cancer (SCLC). Ann Oncol 11:101-108, 2000 (suppl 3)
2. Laurie SA, Logan D, Markman BR, et al: Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer 43:223-240, 2004
3. Bleehen NM, Girling DJ, Machin D, et al: A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC), I: Survival and prognostic factors-Medical Research Council Lung Cancer Working Party. Br J Cancer 68:1150-1156, 1993
4. Siu LL, Shepherd FA, Murray N, et al: Influence of age on the treatment of limited-stage small-cell lung cancer. J Clin Oncol 14:821-828, 1996
5. Poplin E, Thompson B, Whitacre M, et al: Small cell carcinoma of the lung: Influence of age on treatment outcome. Cancer Treat Rep 71: 291-296, 1987
6. Rinaldi M, De Marinis F, Ardizzoni A: Correlation between age and prognosis in patients with advanced non small cancer (NSCLC) treated with cisplatin (DDP) containing chemotherapy: A retrospective multicenter study. Ann Oncol 5:58, 1994 (suppl 8, abstr 0289)
7. Findlay MP, Griffin AM, Raghavan D, et al: Retrospective review of chemotherapy for small cell lung cancer in the elderly: Does the end justify the means? Eur J Cancer 27:1597-1601, 1991
8. Clamon GH, Audeh MW, Pinnick S: Small cell lung carcinoma in the elderly. J Am Geriatr Soc 30:299-302, 1982
9. Radford JA, Ryder WD, Dodwell D, et al: Predicting septic complications of chemotherapy: An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A:81-86, 1992
10. Shepherd FA, Amdemichael E, Evans WK, et al: Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 42:64-70, 1994
11. Gridelli C, De Vivo R, Monfardini S: Management of small-cell lung cancer in the elderly. Crit Rev Oncol Hematol 41:79-88, 2002
12. Girling DJ: Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: A stopped multicentre randomized trial-Medical Research Council Lung Cancer Working Party. Lancet 348:563-566, 1996
13. Souhami RL, Spiro SG, Rudd RM, et al: Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomised comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580, 1997
14. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
15. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
16. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
17. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide-cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 12:2022-2034, 1994
18. Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
19. Ozer H, Armitage JO, Bennet CL, et al: Update of recommendations for the use of hematopietic colony-stimulating factor: Evidence-based, clinical practice guidelines. J Clin Oncol 18:3558-3585, 2000
20. Klastersky J, Paesmans M, Rubenstein EB, et al: The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3051, 2000